Research Analysts Issue Forecasts for Erasca FY2025 Earnings

Key Points

• HC Wainwright analysts have downgraded their FY2025 earnings per share estimate for Erasca to ($0.48), reflecting a minor decrease from the previous estimate of ($0.47).
• Erasca's current full-year earnings consensus forecast is ($0.73) per share, while estimates for future years range from ($0.51) in FY2026 to ($0.01) in FY2029.
• Despite the earnings estimates, Erasca maintains a "Buy" rating from multiple analysts, with a price target ranging between $3.00 and $6.00.

Erasca, Inc. (NASDAQ:ERAS - Free Report) - Research analysts at HC Wainwright reduced their FY2025 earnings per share estimates for Erasca in a report released on Thursday, August 14th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.48) per share for the year, down from their previous forecast of ($0.47). HC Wainwright has a "Buy" rating and a $6.00 price target on the stock. The consensus estimate for Erasca's current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Erasca's FY2026 earnings at ($0.51) EPS, FY2027 earnings at ($0.46) EPS, FY2028 earnings at ($0.27) EPS and FY2029 earnings at ($0.01) EPS.

Erasca (NASDAQ:ERAS - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12).

Separately, Guggenheim set a $3.00 price objective on Erasca and gave the company a "buy" rating in a research note on Wednesday, May 14th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $4.57.

Erasca Trading Up 4.5%

ERAS stock opened at $1.64 on Monday. Erasca has a 1-year low of $1.01 and a 1-year high of $3.31. The firm has a market cap of $465.22 million, a P/E ratio of -3.64 and a beta of 1.07. The business's 50 day moving average is $1.48 and its 200-day moving average is $1.43.

Institutional Investors Weigh In On Erasca

A number of large investors have recently bought and sold shares of ERAS. Geode Capital Management LLC grew its position in Erasca by 1.5% during the 4th quarter. Geode Capital Management LLC now owns 4,569,819 shares of the company's stock worth $11,474,000 after acquiring an additional 67,121 shares during the last quarter. Invesco Ltd. grew its position in Erasca by 30.2% during the 4th quarter. Invesco Ltd. now owns 48,671 shares of the company's stock worth $122,000 after acquiring an additional 11,290 shares during the last quarter. Legal & General Group Plc lifted its holdings in Erasca by 52.8% during the 4th quarter. Legal & General Group Plc now owns 186,825 shares of the company's stock worth $469,000 after buying an additional 64,574 shares in the last quarter. Barclays PLC lifted its holdings in Erasca by 9.8% during the 4th quarter. Barclays PLC now owns 377,764 shares of the company's stock worth $948,000 after buying an additional 33,834 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Erasca during the 4th quarter worth $139,000. 67.78% of the stock is currently owned by institutional investors.

Erasca Company Profile

Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.